首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IFNa10 |
| Uniprot No | P01566 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-189aa |
| 氨基酸序列 | CDLPQTHSLGNRRALILLGQMGRISPFSCLKDRHDFRIPQEEFDGNQFQKAQAISVLHEMIQQTFNLFSTEDSSAAWEQSLLEKFSTELYQQLNDLEACVIQEVGVEETPLMNEDSILAVRKYFQRITLYLIERKYSPCAWEVVRAEIMRSLSFSTNLQKRLRRKD |
| 预测分子量 | 21.4kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IFNα10重组蛋白的示例参考文献(注：部分信息为示例性概括，实际文献需通过学术数据库查询)：
1. **文献名称**：*Recombinant human interferon alpha-10: Cloning, expression, and functional characterization*
**作者**：Smith J, et al.
**摘要**：该研究报道了人IFNα10基因的克隆及在大肠杆菌中的重组表达，纯化后的蛋白在体外实验中显示出对病毒复制的抑制作用，并激活了典型干扰素信号通路(STAT1磷酸化)。
2. **文献名称**：*Antiviral activity of IFNα10 against hepatitis B virus in vitro*
**作者**：Li Y, et al.
**摘要**：研究发现重组IFNα10能显著抑制HBV病毒DNA的复制，并降低肝细胞中病毒抗原表达，提示其潜在抗肝炎病毒应用价值。
3. **文献名称**：*Comparative analysis of type I interferon subtypes in cancer immunotherapy*
**作者**：Wang H, et al.
**摘要**：该研究对比了多种干扰素α亚型的抗肿瘤活性，发现重组IFNα10可通过增强NK细胞活性及肿瘤细胞MHC-I表达，抑制黑色素瘤小鼠模型的肿瘤生长。
4. **文献名称**：*Structural basis of IFNα10 receptor binding specificity*
**作者**：Zhang R, et al.
**摘要**：通过晶体学分析揭示了IFNα10与IFNAR受体复合物的结合模式，阐明了其与其他α亚型干扰素不同的受体亲和力特征。
**注意事项**：
- 上述文献信息为示例，实际研究需通过PubMed、Web of Science等平台检索。
- 建议使用关键词 "Recombinant IFNα10"、"Interferon alpha-10" 或 "IFNA10" 进行精准查询，并关注2015年后发表的文献以获取最新进展。
Interferon-alpha 10 (IFNα10), a member of the type I interferon family, is a cytokine with critical roles in innate immunity, viral defense, and immune regulation. It is encoded by the *IFNA10* gene in humans and shares structural homology with other IFNα subtypes, featuring a conserved helical bundle core. Recombinant IFNα10 is produced through genetic engineering, typically using bacterial (e.g., *E. coli*) or mammalian expression systems. The bacterial-derived protein lacks glycosylation, while mammalian systems (e.g., CHO cells) yield glycosylated forms closer to native human IFNα10.
Functionally, IFNα10 binds to the IFN-α/β receptor (IFNAR), activating the JAK-STAT signaling pathway to induce interferon-stimulated genes (ISGs). These genes mediate antiviral, antiproliferative, and immunomodulatory effects. Unlike some IFNα subtypes, IFNα10 exhibits distinct receptor-binding kinetics and signaling dynamics, potentially influencing its biological specificity. Studies suggest it may play unique roles in viral inhibition (e.g., HBV, HIV) and tumor suppression, though its activity overlaps partially with other IFNα members.
Recombinant IFNα10 is widely used in research to dissect subtype-specific interferon functions, optimize therapeutic strategies, and model immune responses. Its clinical potential is explored in antiviral therapies, cancer immunotherapy, and autoimmune disease management. For example, IFNα10 has been investigated in combination therapies for chronic hepatitis B and COVID-19 due to its robust antiviral properties. Production of recombinant IFNα10 requires stringent quality control, including HPLC, SDS-PAGE, and bioactivity assays (e.g., antiviral cytopathic effect inhibition), to ensure purity and functionality.
Overall, IFNα10 recombinant protein serves as a valuable tool for understanding interferon biology and developing targeted immunotherapies, bridging gaps between subtype-specific mechanisms and clinical applications.
×
